November 29, 2016 - By Dolores Ford
Today, an important insider trading deal was made. Joe Kiani, the CEO and Chairman of the Board and an insider of Masimo Corp sold precisely 104,870 shares of Masimo Corp, worth close to $6,530,527 U.S Dollars, at $62.3 for each share at the time of the deal. Joe is trying to quietly decrease his company’s share, same as he did in the last 30 days. He unloaded another 106,152 shares worth $6,587,271 USD. The sale was revealed in a SEC Form 4 on November 29, 2016. Joe Kiani now has ownership of 3.05 million shares which are equivalent to roughly 6.09% of the California-based company’s total market capitalization.
Out of 3 analysts covering Masimo (NASDAQ:MASI), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. $51 is the highest target while $46 is the lowest. The $48.50 average target is -21.95% below today’s ($62.14) stock price. Masimo has been the topic of 3 analyst reports since August 5, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating by TH Capital given on Wednesday, August 5. On Wednesday, January 6 the stock rating was downgraded by Raymond James to “Outperform”.
Insitutional Activity: The institutional sentiment increased to 1.33 in 2016 Q2. Its up 0.01, from 1.32 in 2016Q1. The ratio increased, as 14 funds sold all Masimo Corporation shares owned while 85 reduced positions. 52 funds bought stakes while 79 increased positions. They now own 38.69 million shares or 0.37% less from 38.84 million shares in 2016Q1.
Arizona State Retirement Sys owns 22,842 shares or 0.02% of their US portfolio. Deere And has invested 0.07% of its portfolio in Masimo Corporation (NASDAQ:MASI). Citigroup last reported 0% of its portfolio in the stock. First Bank Of Omaha last reported 13,525 shares in the company. Raymond James & Associate has invested 0.02% of its portfolio in Masimo Corporation (NASDAQ:MASI). Gabelli Funds Ltd accumulated 122,000 shares or 0.04% of the stock. Patten Group Inc Inc reported 115 shares or 0% of all its holdings. Fuller Thaler Asset Incorporated holds 0.78% of its portfolio in Masimo Corporation (NASDAQ:MASI) for 866,667 shares. Amalgamated Savings Bank holds 0.02% or 4,757 shares in its portfolio. State Of Tennessee Treasury Department holds 0.06% of its portfolio in Masimo Corporation (NASDAQ:MASI) for 210,614 shares. Turner Invs Ltd Partnership has 0.36% invested in the company for 22,000 shares. Oxford Asset Management has 0.3% invested in the company for 136,701 shares. Adams Diversified Equity Fund, a Maryland-based fund reported 10,100 shares. Moreover, Fifth Third Bancshares has 0.01% invested in Masimo Corporation (NASDAQ:MASI) for 12,718 shares. Tiaa Cref Investment Mngmt Ltd Llc reported 214,179 shares or 0.01% of all its holdings.
Insider Transactions: Since May 31, 2016, the stock had 0 insider buys, and 25 sales for $31.52 million net activity. 4,000 shares were sold by Coleman Jon, worth $200,000. 2,000 Masimo Corporation (NASDAQ:MASI) shares with value of $119,623 were sold by FITCH SANFORD. KIANI JOE E had sold 84,617 shares worth $5.10M. The insider Jansen Paul sold 10,000 shares worth $588,800. The insider Van Ramshorst David J sold 5,000 shares worth $262,500. 30,000 shares were sold by Lee Yongsam, worth $1.82M. $590,000 worth of shares were sold by McClenahan Thomas Samuel on Friday, September 30.
The stock increased 0.60% or $0.37 during the last trading session, hitting $62.14. About 297,312 shares traded hands. Masimo Corporation (NASDAQ:MASI) has risen 42.26% since April 26, 2016 and is uptrending. It has outperformed by 37.00% the S&P500.
Masimo Corporation is a medical technology firm that develops, makes and markets non-invasive patient monitoring products. The company has a market cap of $3.05 billion. The Company’s business is measure-through-motion and low-perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology pulse oximetry. It has a 29.96 P/E ratio. The Company’s product offerings include monitoring blood constituents with an optical signature, optical organ oximetry monitoring, electrical brain function monitoring, acoustic respiration monitoring and exhaled gas monitoring.
According to Zacks Investment Research, “Masimo develops innovative monitoring technologies that significantly improve patient care — helping solve unsolvable problems. The company debuted Read-Through Motion and Low Perfusion pulse oximetry, known as SET, and with it substantially reduced false alarms and increased pulse oximetry’s ability to detect life-threatening events. Our Masimo SET platform has significantly addressed many of the previous technology limitations, has substantially contributed to improved patient outcomes and has been referred to by several industry sources as the gold standard in pulse oximetry. Masimo has introduced Masimo Rainbow SET Pulse CO-Oximetry, which, for the first time, noninvasively monitors the level of carbon monoxide and methemoglobin in the blood, allowing early detection and treatment of potentially life-threatening conditions. Masimo has the mission of Improving Patient Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications.”
Analysts await Masimo Corporation (NASDAQ:MASI) to report earnings on February, 28. They expect $0.51 EPS, up 240.00% or $0.36 from last year’s $0.15 per share. MASI’s profit will be $25.03M for 30.46 P/E if the $0.51 EPS becomes a reality. After $0.47 actual EPS reported by Masimo Corporation for the previous quarter, Wall Street now forecasts 8.51% EPS growth.
Masimo Corporation, incorporated on May 7, 1996, is a medical technology firm that develops, makes and markets non-invasive patient monitoring products. The Company’s business is measure-through-motion and low-perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry. The Company’s product offerings include monitoring blood constituents with an optical signature, optical organ oximetry monitoring, electrical brain function monitoring, acoustic respiration monitoring and exhaled gas monitoring. In addition, the Company has developed the Root patient monitoring and connectivity platform, the Radical-7 bedside and portable patient monitor and the Radius-7 wearable wireless patient monitor. It has also developed the Patient SafetyNet remote patient surveillance monitoring system, which allows over 200 patients to be monitored simultaneously and remotely through a personal computer (PC) viewing station or by care providers through their pagers, voice-over-Internet Protocol (IP) phones or smartphones.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Dolores Ford